Business
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity ...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models\nBria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line modelsImmune cells activated by Bria-OTS+ exhibit serial killing activity across multiple rounds of tumor cell challenge PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17–22 at the San Diego Convention Center in San Diego, California. The poster is summarized below and linked here: https://briacell.com/scientific-publications/. Title: Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor ResponsesSession Category: Clinical ResearchSession Title: Vaccines and Other Immunomodulatory AgentsSession: 4/21/2026 2:00-5:00 PMLocation: Poster Section 49Poster Board Number: 12Poster Number: 6701 Summary: Bria-OTS+ is a personalized, off-the-shelf, next-generation genetically engineered whole-cell cancer immunotherapy platform designed to enhance efficacy and safety. Our results demonstrate that Bria-OTS+ activates key components of both the innate and adaptive immune systems to broadly target and destroy cancer cells across solid tumors. These effects include coordinated activation of CD4⁺ and CD8⁺ T cells, NK cells, NKT cells, dendritic cells, and B cells, together with increased cytokine release and sustained immune competence without exhaustion—helping address an important mechanism of cancer progression. Data presented includes the following: Rapid activation of innate and adaptive immune responses: Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer) drove early activation and proliferation of key immune cells including CD4+ and CD8+ T cells, NK cells, and NKT cells, enhanced cytotoxic activity against parental tumor targets, and increased CD80/CD86 expression on dendritic and B cells, consistent with improve...